non-small cell lung cancer

Guardant Health nabs FDA test approval for BI's new cancer drug

Boehringer Ingelheim’s Hernexeos has nabbed a companion diagnostic from Guardant Health after the FDA cleared its liquid biopsy test, Guardant360 CDx.

Ben Adams Jun 12, 2026 9:47am

GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer

Jun 9, 2026 4:41am

ASCO: Takeda touts ‘tremendous potential’ of Innovent bispecific

Jun 2, 2026 4:30am

Fierce Pharma

Akeso's 34% overall survival win comes with caveats

May 31, 2026 8:00am

Graphic of a fork in the road with arrows pointing in either direction

ASCO: BioNTech/BMS, Pfizer split on bispecific approach in NSCLC

May 30, 2026 3:30pm

Kura posts data on drug designed to unleash KRAS inhibitors

May 26, 2026 10:09am